Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 [norclozapine] in Acutely Psychotic Subjects With Schizophrenia

Next Previous
X
Search
Trial Profile

A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 [norclozapine] in Acutely Psychotic Subjects With Schizophrenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Norclozapine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Acadia Pharmaceuticals

    • Most Recent Events

    • 16 Jun 2008 Results data have been reported in an ACADIA Pharmaceuticals media release.
    • 06 Mar 2008 The treatment phase of the trial has been completed.
    • 15 Dec 2007 Top-line results are expected in the second quarter of 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top